MM120 · program
Lysergide D-tartrate (MM120 / LSD) for Major depressive disorder
Indications for MM120: Generalized anxiety disorder · Phase 3 Attention-deficit/hyperactivity disorder · Discontinued Major depressive disorder · Phase 3 Post-traumatic stress disorder · Phase 3
MM120 (DT120) for major depressive disorder — second indication after the lead GAD program. Phase 3 'Emerge' study (NCT06941844) evaluates a single dose for MDD. Builds on MM120's Phase 2b anxiety data and the GAD Phase 3 program (Voyage/Panorama).
Development timeline
- Phase 3 MDD program (Emerge, NCT06941844) initiated. Date approximate.
Clinical trials in Major depressive disorder
NCT07592689Phase 3Recruitingn=165
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
NCT06941844EmergePhase 3Recruiting
Phase 3 Study of MM120 (Lysergide) in Major Depressive Disorder (Emerge)
Formulations
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| DT120 orally disintegrating tablet (ODT)Orally disintegrating tablet (ODT) using Catalent Zydis fast-dissolve technology Proprietary orally disintegrating tablet of lysergide (LSD) D-tartrate; single administration; designed for faster absorption and onset | Oral | Single dose | — |
Mechanism of action
LSD acts across serotonin receptor subtypes; the company describes MM120 as a 5-HT2A partial agonist (IUPHAR classifies LSD as a full 5-HT2A agonist). Antidepressant effects attributed primarily to 5-HT2A agonism.
| Target | Action | Affinity |
|---|---|---|
| 5-HT2AprimaryHTR2A | Partial agonist | pKi 9.4ⓘ |
| 5-HT1AHTR1A | Agonist | pKi 9ⓘ |
| 5-HT2CHTR2C | Agonist | pKi 8.2ⓘ |
← Full MM120 compound page (identity, identifiers, all indications)
Sources
- DT120 ODT — LSD Therapy for Depression and Anxiety — Definium Therapeutics
- clinicaltrials.gov — clinicaltrials.gov
- Lysergide (LSD), Ligand 17 — IUPHAR/BPS
- MM120 Emerge Phase 3 MDD (NCT06941844) — ClinicalTrials.gov